Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination
Blood Immunology & Cellular Therapy Cover Image for Volume 1, Issue 3
Current Issue
Volume 1,
Issue 3,
December 2025
View This Issue
ISSUES IN PROGRESS
Volume 1, Issue 3, December 2025

What is Blood Immunology & Cellular Therapy?

Blood Immunology & Cellular Therapy provides an international platform for publishing original research in basic, translational, and clinical investigations related to cellular and non-cellular immunotherapies for hematological conditions and the underlying immunology.

The full scope is available on Blood ICT's About page.

Latest Articles

Lipid nanoparticle Fas gene therapy suppresses autoimmune lymphoproliferative syndrome in mice
Delay in CAR-T from Single Case Agreements: Real-World Impact on Treatment & Outcomes in at least Twice-Refractory DLBCL
Modeling Vγ9Vδ2 T Cell Exhaustion In Vitro: Phenotypic and Functional Insights for Immunotherapy
Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning
Low-dose Nivolumab and Lenalidomide in Relapsed/Refractory Hodgkin Lymphoma - A Single Arm Phase II Trial
Selinexor-based treatments are associated with increased expression of T cell activation markers in multiple myeloma
Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia
Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma
Early ICANS recognition with a novel electroencephalogram-based deltawave detection system in patients receiving CAR T-cell therapy
Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience

Advertisement intended for health care professionals

ASH Commitment to Expansion and Inclusion in Hematology

Featured Content

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry

Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory

Combining antigen-specific T cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 

Advertisement intended for health care professionals

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals